Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK.

JAMA Oncol. 2019 Jan 1;5(1):45-50. doi: 10.1001/jamaoncol.2018.3691.

2.

Isolated Contralateral Axillary Lymph Node Involvement in Breast Cancer Represents a Locally Advanced Disease Not Distant Metastases.

Chkheidze R, Sanders MAG, Haley B, Leitch AM, Sahoo S.

Clin Breast Cancer. 2018 Aug;18(4):298-304. doi: 10.1016/j.clbc.2017.10.019. Epub 2017 Nov 10.

PMID:
29233470
3.

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M.

JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.

4.

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.

Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER.

Ann Oncol. 2017 May 1;28(5):1070-1077. doi: 10.1093/annonc/mdx048.

5.

Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.

Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK.

Ann Surg. 2016 Sep;264(3):413-20. doi: 10.1097/SLA.0000000000001863.

6.

Response to preoperative endocrine therapy in breast cancer patients can alter surgical and chemotherapy options.

Leitch AM, Boughey JC, Hunt KK.

Bull Am Coll Surg. 2015 Nov;100(11):43-5. No abstract available.

PMID:
26677537
7.

Oxidative stress inhibits distant metastasis by human melanoma cells.

Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ, Morrison SJ.

Nature. 2015 Nov 12;527(7577):186-91. doi: 10.1038/nature15726. Epub 2015 Oct 14.

8.
9.

Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Kuerer HM, Bowling M, Hunt KK; Alliance for Clinical Trials in Oncology.

Ann Surg. 2015 Mar;261(3):547-52. doi: 10.1097/SLA.0000000000000551.

10.

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer.

Bao J, Borja N, Rao M, Huth J, Leitch AM, Rivers A, Wooldridge R, Rao R.

Cancer Med. 2015 Apr;4(4):500-6. doi: 10.1002/cam4.388. Epub 2015 Jan 30.

11.

Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.

Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK.

Ann Surg. 2014 Oct;260(4):608-14; discussion 614-6. doi: 10.1097/SLA.0000000000000924.

12.

Analysis of internet usage among cancer patients in a county hospital setting: a quality improvement initiative.

Wallace L, Lilley L, Lodrigues W, Dreadin-Pulliam J, Xie XJ, Mathur S, Rao M, Harvey V, Leitch AM, Rao R.

JMIR Res Protoc. 2014 May 9;3(2):e26. doi: 10.2196/resprot.2806.

13.

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK; American College of Surgeons Oncology Group investigators.

Lancet Oncol. 2013 Dec;14(13):1317-25. doi: 10.1016/S1470-2045(13)70502-3. Epub 2013 Nov 13.

14.

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliance for Clinical Trials in Oncology.

JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.

15.

Management of locoregional and systemic recurrence of breast cancer: to stage or not to stage and how.

Leitch AM.

Ann Surg Oncol. 2013 Oct;20(10):3194-8. doi: 10.1245/s10434-013-3180-6. Epub 2013 Aug 22.

PMID:
23975310
16.

Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial.

Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE.

Ann Surg. 2012 Sep;256(3):428-36.

17.

Influence of surgical technique on mastectomy and reexcision rates in breast-conserving therapy for cancer.

Unzeitig A, Kobbermann A, Xie XJ, Yan J, Euhus D, Peng Y, Sarode V, Moldrem A, Leitch AM, Andrews V, Rao R.

Int J Surg Oncol. 2012;2012:725121. doi: 10.1155/2012/725121. Epub 2012 Jan 16.

18.

Evaluation of a hydrogel based breast biopsy marker (HydroMARK®) as an alternative to wire and radioactive seed localization for non-palpable breast lesions.

Klein RL, Mook JA, Euhus DM, Rao R, Wynn RT, Eastman AB, Leitch AM.

J Surg Oncol. 2012 May;105(6):591-4. doi: 10.1002/jso.22146. Epub 2011 Nov 17.

PMID:
22095610
19.

Volume of excision and cosmesis with routine cavity shave margins technique.

Mook J, Klein R, Kobbermann A, Unzeitig A, Euhus D, Peng Y, Sarode V, Moldrem A, Leitch AM, Andrews V, Teotia S, Rao R.

Ann Surg Oncol. 2012 Mar;19(3):886-91. doi: 10.1245/s10434-011-1982-y. Epub 2011 Aug 12.

PMID:
21837529
20.

Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer.

Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt KK, McCall LM, Abati A, Cote R.

JAMA. 2011 Jul 27;306(4):385-93. doi: 10.1001/jama.2011.1034.

21.

American College of Surgeons Oncology Group and the community surgeon.

Ota DM, Leitch AM, Unzeitig G.

Surg Oncol Clin N Am. 2011 Jul;20(3):439-45, vii. doi: 10.1016/j.soc.2011.01.006. Review.

22.

Aesthetic subunit of the breast: an analysis of women's preference and clinical implications.

Bailey SH, Saint-Cyr M, Oni G, Maia M, Andry D, Shirvani A, Nguyen V, Wong C, Zhang S, Leitch AM, Euhus D, Rao R, Rohrich R.

Ann Plast Surg. 2012 Mar;68(3):240-5. doi: 10.1097/SAP.0b013e318216b563.

PMID:
21629084
23.

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M.

JAMA. 2011 Feb 9;305(6):569-75. doi: 10.1001/jama.2011.90.

24.

Delays in time to treatment and survival impact in breast cancer.

Brazda A, Estroff J, Euhus D, Leitch AM, Huth J, Andrews V, Moldrem A, Rao R.

Ann Surg Oncol. 2010 Oct;17 Suppl 3:291-6. doi: 10.1245/s10434-010-1250-6. Epub 2010 Sep 19.

PMID:
20853049
25.

Controversies in breast surgery.

Boughey JC, Mittendorf EA, Solin LJ, Michael Dixon J, Tuttle TM, Beitsch PD, Cody HS, Leitch AM, Newman LA.

Ann Surg Oncol. 2010 Oct;17 Suppl 3:230-2. doi: 10.1245/s10434-010-1264-0. Epub 2010 Sep 19. No abstract available.

PMID:
20853038
26.

Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K.

Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3. doi: 10.1097/SLA.0b013e3181f08f32.

27.

Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010.

Wilke LG, Ballman KV, McCall LM, Giuliano AE, Whitworth PW, Blumencranz PW, Reintgen DS, Burak WE, Leitch AM, Hunt KK.

Ann Surg Oncol. 2010 Aug;17(8):1989-94. doi: 10.1245/s10434-010-0980-9. Epub 2010 Mar 23.

28.

Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011.

Olson JA Jr, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE; American College of Surgeons Oncology Group Trials Z0010 and Z0011.

J Clin Oncol. 2008 Jul 20;26(21):3530-5. doi: 10.1200/JCO.2007.15.5630.

PMID:
18640934
29.

False-positive sentinel lymph nodes in breast cancer patients caused by benign glandular inclusions: report of three cases and review of the literature.

Peng Y, Ashfaq R, Ewing G, Leitch AM, Molberg KH.

Am J Clin Pathol. 2008 Jul;130(1):21-7; quiz 146. doi: 10.1309/JVB8QFQNW5HBN7UJ. Review.

PMID:
18550466
30.

DNA methylation in benign breast epithelium in relation to age and breast cancer risk.

Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, Lewis CM.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1051-9. doi: 10.1158/1055-9965.EPI-07-2582.

31.

Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk.

Euhus DM, Bu D, Ashfaq R, Xie XJ, Bian A, Leitch AM, Lewis CM.

Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1812-21.

32.

Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007.

Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M.

Ann Surg Oncol. 2007 Sep;14(9):2425-7. Epub 2007 Jun 28. No abstract available.

PMID:
17597344
33.

Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE; American College of Surgeons Oncology Group.

J Clin Oncol. 2007 Aug 20;25(24):3657-63. Epub 2007 May 7.

PMID:
17485711
34.

Patient variables that predict atypical cytology by nipple duct lavage.

Bushnaq ZI, Ashfaq R, Leitch AM, Euhus D.

Cancer. 2007 Apr 1;109(7):1247-54.

35.

Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.

Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE.

Ann Surg Oncol. 2006 Apr;13(4):491-500. Epub 2006 Mar 2.

PMID:
16514477
36.

CASE 4. Fibrocystic breast disease in a 16-year-old female with PTEN hamartoma tumor syndrome.

Patterson AR, Leitch AM, Weatherall P, Zhou XP, Eng C, Tomlinson GE.

J Clin Oncol. 2006 Jan 20;24(3):525-7. No abstract available.

PMID:
16421431
37.

Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.

Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, Hunt KK, Giuliano AE.

Am J Surg. 2005 Oct;190(4):539-42.

PMID:
16164916
38.

Reproducibility of cytologic atypia in repeat nipple duct lavage.

Johnson-Maddux A, Ashfaq R, Cler L, Naftalis E, Leitch AM, Hoover S, Euhus DM.

Cancer. 2005 Mar 15;103(6):1129-36.

39.

Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.

Lewis CM, Cler LR, Bu DW, Zöchbauer-Müller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM.

Clin Cancer Res. 2005 Jan 1;11(1):166-72.

40.

Patient and duct selection for nipple duct lavage.

Maddux AJ, Ashfaq R, Naftalis E, Leitch AM, Hoover S, Euhus D.

Am J Surg. 2004 Oct;188(4):390-4.

PMID:
15474432
41.

Clinical relevance of reverse transcriptase-polymerase chain reaction for the detection of axillary lymph node metastases in breast cancer.

Sakaguchi M, Virmani A, Dudak MW, Peters GN, Leitch AM, Saboorian H, Gazdar AF, Euhus DM.

Ann Surg Oncol. 2003 Mar;10(2):117-25.

PMID:
12620905
42.

Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk.

Euhus DM, Cler L, Shivapurkar N, Milchgrub S, Peters GN, Leitch AM, Heda S, Gazdar AF.

J Natl Cancer Inst. 2002 Jun 5;94(11):858-60.

PMID:
12048275
43.

Validating the performance of the mammary sentinel lymph node team.

Euhus DM, Peters GN, Leitch AM, Saboorian H, Mathews D, Erdman W, Anglin B, Huth J.

J Surg Oncol. 2002 Apr;79(4):209-15.

PMID:
11920777
44.

Limitations of the Gail model in the specialized breast cancer risk assessment clinic.

Euhus DM, Leitch AM, Huth JF, Peters GN.

Breast J. 2002 Jan-Feb;8(1):23-7.

PMID:
11856157
45.

MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation.

Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM.

J Magn Reson Imaging. 2001 Jun;13(6):868-75.

PMID:
11382946
46.

What's new in surgical oncology.

Leitch AM.

J Am Coll Surg. 2001 May;192(5):624-39. Review. No abstract available.

PMID:
11333100
47.

Breast cancer: screening and early detection.

Leitch AM.

Tex Med. 2001 Feb;97(2):74-8. Review.

PMID:
11233064
48.

Breast cancer screening: success amid conflict.

Leitch AM.

Surg Oncol Clin N Am. 1999 Oct;8(4):657-72, vi. Review.

PMID:
10452933
49.

American Cancer Society Lymphedema Workshop. Workgroup I: Treatment of the axilla with surgery and radiation--preoperative and postoperative risk assessment.

Leitch AM, Meek AG, Smith RA, Boris M, Bourgeois P, Higgins S, Pressman PI, Stevens J, Stevens RE.

Cancer. 1998 Dec 15;83(12 Suppl American):2877-9. Review. No abstract available.

PMID:
9874415
50.

Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.

Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD, Shay JW.

Int J Cancer. 1998 Dec 9;78(6):766-74.

Supplemental Content

Loading ...
Support Center